HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G Ventures Startup Incubator Yields Supplements For Menopause Symptoms

Executive Summary

P&G Ventures startup's partnership with venture capital group M13 delivered its first brand, the Kindra four-product, hormone-free menopausal line. Kindra says its products provide relief from the seven symptoms of menopause in a market largely neglected.

You may also be interested in...

P&G Clearblue Line Extension, Kenvue Survey Of 4,500 Women Target Menopause Market

P&G announces Clearblue Menopause Stage Indicator launch noting more than two in three women feel unprepared for menopause and less than half say they have enough information to manage it. Kenvue survey results show prior to age 50, proportion of women experiencing symptoms attributable to menopause is significantly greater than the proportion that self-reports.

Lady Patch For Preventing Bladder Leaks Wins P&G Ventures Innovation Challenge

ParaPatch developed patch to commercialize a home remedy and was chosen from a record number of submissions in contest. It will receive $10,000 and opportunity to partner with P&G Ventures to continue development.

Blooming For Spring: P&G My Black Is Beautiful, Dollar General Root To End! Hair Products

My Black is Beautiful hair care expands with Blue Ginger six-product line for scalp and hair nourishment, rolling out in Sally Beauty, says P&G. Retail chain Dollar General expands its private label offerings with hair care line Root to End!

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts